Drugs / ginsenoside-Rd
ginsenoside-Rd
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00591084 | Sep 2005 → Jun 2006 | ischemic stroke | Xijing Hospital | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00815763 | Sep 2006 → Jun 2008 | ischemic stroke | Xijing Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ginsenoside-Rd | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00815763 ↗ |
| Known as | Chikusetsusaponin fk7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL473659 ↗ |
| Known as | Gypenoside viii | ChEMBL registry synonym — accepted as the source's own label CHEMBL473659 ↗ |
| Action | Inhibit | “Ginsenoside-Rd has been shown to inhibit receptor-operated Ca2+ influx through receptor-and-store-operated Ca2+ channels (ROCC)” NCT00591084 ↗ |